Breaking Finance News

Zacks Investment Research upgraded Aimmune Therapeutics Inc (NASDAQ:AIMT) to Hold in a statement released earlier today.

Boasting a price of $15.85, Aimmune Therapeutics Inc (NASDAQ:AIMT) traded 0.64% lower on the day. With the last stock price close up 14.24% relative to the 200-day average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has registered a 50-day average of $13.89 and two hundred day moving average of $13.67. Trading volume was was down over the average, with 104,326 shares of AIMT changing hands under the typical 212,558 shares.

Zacks Investment Research has upgraded Aimmune Therapeutics Inc(NASDAQ:AIMT) to Hold in a report released Monday September 19 2016.

Performance Graph:

Aimmune Therapeutics Inc (NASDAQ:AIMT)

Aimmune Therapeutics Inc has a one-year low of $9.77 and a one-year high of $26.50 . Aimmune Therapeutics Inc’s market capitalization is presently $0.0.

General Information About Aimmune Therapeutics Inc (NASDAQ:AIMT)

Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation. For patients in the up-dosing phase of the AR101 treatment regimen, and AR101 would be provided in a series of color coded pharmaceutical grade capsules of various dose levels.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *